Compare Nutrien Ltd (NTR) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Nutrien Ltd trades at $70.33 (market cap $33.31B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.69 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 59 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| NTR | TAK | |
|---|---|---|
Market Cap | $33.31B | $58.74B |
Volume | 1,330,729 | 3,110,994 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $19.05 |
52-Week Low | $53.64 | $13.23 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $45.11B | $86.65B |
Dividend Yield | 3.15% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $69.97, down 1.73% today, with mixed technical signals showing bearish moving averages but oversold RSI levels. The company maintains solid fundamentals with $26.89B revenue, 8.44% net margin, and attractive valuation at P/E of 14.14. Recent earnings show volatility with Q2 2026 missing estimates but Q1 beating expectations, while analyst consensus remains bullish with $76.14 price target.
NTR presents value opportunity with reasonable valuation and strong agricultural market positioning, though faces headwinds from fertilizer price volatility and competitive pressures. The stock's current discount to analyst targets and oversold technical condition suggest potential upside, but investors should monitor input cost trends and global fertilizer demand dynamics closely.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
